Scotiabank analyst Louise Chen turned bullish on Big Pharma. She raised her target on MRK to $180 from $155. AMGN got an even bigger boost — target lifted to $500 from $450. Both carry Buy ratings. Merck's market cap stands at $367 billion. Amgen sits at $226 billion.
WBD moved the other way. The consensus rating on Warner Bros. Discovery slipped to a downgrade, with one analyst cutting the stock. The media giant is navigating a tough streaming environment.
Energy names took target cuts from Jefferies. Lloyd Byrne trimmed EQT to $73 from $75. He also cut BKR to $77 from $80. Both retain Buy ratings despite the reductions.
In retail, Evercore ISI split its calls. Analyst Greg Melich cut DLTR to $135 from $140. But he raised BBY to $90 from $85. Both stocks are rated Hold.
DA Davidson initiated AKAM at Buy with a $150 target. That adds to growing coverage of cloud infrastructure names.
The biggest single-stock theme today: pharma optimism versus media caution.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
